Arthrex Hip’s Post

5 Things to Know - Thing 1) Shockwave Medical $SWAV Being Acquired by Johnson & Johnson $JNJ: DKI Takeaway: DKI recommended Shockwave Medical $SWAV to subscribers in December at $190. Our positive thesis was based on an expected takeover for more than $300 per share. Boston Scientific $BSX approached Shockwave last year. They could return to bid again, but given that the $JNJ talks have been public for more than a week and that there’s now a breakup fee, it’s possible but unlikely they re-enter the situation. DKI subscribers made more than 70% in under four months. This is the second DKI portfolio company to be acquired following Houghton Mifflin which was bought for more than 4x DKI’s initial purchase price. If that’s of interest to you, you’re welcome to subscribe. Otherwise, we’ll be happy to keep informing you after the fact. https://lnkd.in/eZBfFWkW

5 Things to Know - Thing 1) Shockwave Medical $SWAV Being Acquired by Johnson & Johnson $JNJ: DKI Takeaway: DKI recommended Shockwave Medical $SWAV to subscribers in December at $190. Our positive thesis was based on an expected takeover for more than $300 per share. Boston Scientific $BSX approached Shockwave last year. They could return to bid again, but given that the $JNJ talks have been public for more than a week and that there’s now a breakup fee, it’s possible but unlikely they re-enter the situation. DKI subscribers made more than 70% in under four months. This is the second DKI portfolio company to be acquired following Houghton Mifflin which was bought for more than 4x DKI’s initial purchase price. If that’s of interest to you, you’re welcome to subscribe. Otherwise, we’ll be happy to keep informing you after the fact. https://lnkd.in/gV5RdcGT

📢 Exciting announcement! 📢 The KMPF annual report for 2022-23 is out now, offering insights into the impact of our initiatives over the past year. Discover more about who we are, what we do, and our plans for the future. View the digital report below (link in comments) 👇 #KMPF #UniConnect

Read about how experts are redefining the standard in PE care in our latest supplement celebrating 10 years of The National PERT Consortium. | #Sponsored by The PERT Consortium

At PCR London Valves, Dr. Andreas Rück will present about his experience with DurAVR® THV in a rare TAV-in-TAV-in-SAV case from earlier this year. The DurAVR® valve was implanted via compassionate use approval in Sweden. Dr. Rück will present case footage and firsthand insights. “DurAVR® allowed us to treat a patient who was deemed unsuitable for surgical intervention or in fact other TAVRs. The device was easy to use and allowed us to implant the valve in a predictable way. Further, it has provided the patient with the best functioning valve since before his first valve replacement, this despite it being placed inside two other valves.” - Dr Andreas Rück #ViV #valveinvalve #TAVI #TAVR #aorticstenosis #PCRLV DurAVR® INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE.   EU: Exclusively for clinical investigations. US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use. 

hVIVO PLC (AIM:HVO) chief executive Yamin (Mo) Khan speaks with Proactive's Stephen Gunnion about the company's achievements in the first half of 2024, including a 31% increase in revenue, reaching £35.6 million. Khan highlighted the company's record EBITDA of £8.7 million, reflecting a 68% year-on-year growth. He attributed these successes to the opening of the world’s largest human challenge trial facility in Canary Wharf, which includes 50 beds for CL3 level pathogen trials. Khan also spoke about hVIVO’s strategic expansion of service offerings beyond human challenge trials, including laboratory services and patient recruitment via its FluCamp platform. He emphasised the company’s strong order book, valued at £71 million, and its sales pipeline, which includes £40 million worth of opportunities. As hVIVO looks ahead, Khan reiterated the company’s guidance for 2024 revenue of £62 million and an EBITDA margin at the... Watch at #Proactive #ProactiveInvestors http://ow.ly/1Xze105IcW7

"NC Medical Portfolio Acquired by AW for $55.2M in 9-Property Deal" Read the full article below..

I just checked out this great review on Medtronic’s new Simplera CGM! 🎥 It’s exciting to see how CGM technology is evolving and making diabetes management more seamless. If you’re curious about Simplera or thinking of trying it, give this video a watch for some firsthand insights. #CGM #DiabetesTech #Simplera #Medtronic

Exciting insights on the Certified Durable Medical Equipment Specialist (CDME) credential and its career-transforming potential in the DME field! 🚀 Navigating the #dme landscape demands not just experience and knowledge. That's where the CDME credential comes in, offering a distinctive edge by affirming your in-depth knowledge and commitment to the DMEPOS field. It stands out for its focused relevance to DME, making it the only credential of its kind to validate your status as an industry expert. 🌟 Achieving CDME isn't just about adding a title—it's about elevating your career possibilities and setting a new standard in professional excellence. It opens up new opportunities and signifies your role as a leader and innovator in the field. 🔑 The CDME community represents a network of dedicated professionals who are acknowledged for their expertise and forward-thinking in #dme . If you're aiming to solidify your position in the DME sector, the CDME credential can be your gateway to becoming an industry leader. 💼 #CDME #DMEExpertise #CareerAdvancement #ProfessionalGrowth #IndustryLeadership

#cardiacmarker #NTproBNP #Troponin #CLIA #AUTOMATION #IVD Cardiac biomarkers 💓 play a pivotal role in the timely diagnosis, accurate management, and prognosis of cardiovascular conditions. Let’s delve into their significance: "Diagnosis in the Golden Period" ⏲ When someone experiences chest pain or other symptoms suggestive of acute coronary syndrome (ACS), rapid diagnosis becomes critical. Cardiac biomarkers help identify myocardial damage early, allowing prompt initiation of therapy. The golden period refers to the crucial window when intervention can potentially reverse myocardial injury. Accurate diagnosis during this phase is essential. "Powerful Triage Tool" 🔬 In emergency departments, where time is of the essence, cardiac biomarkers aid in triaging patients. By assessing these markers, healthcare professionals can prioritize cases, ensuring that those with high-risk profiles receive immediate attention. "Myocardial Damage Assessment" 👨⚕️ Cardiac biomarkers provide insights into the extent of myocardial damage. They help differentiate between unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI). RealMind Biotech MCL60 Delicate, Ultra-fast, Diagnostic Platform which can run a high sensitive cardiac panel - hs-cTnT & NT-proBNP within 13mins automatically. Let's see the operation process via our youtube chanel. Welcome to subscribe and follow us on Linkedln! We will share more acknowledge and funs story of IVD. 😘